We are live on ! Find out more

Wave Life Sciences

WVE

Market cap $1.03B

5.25 USD

+0.13

2.54%

At close Updated Aug 25, 4:00 PM EDT

Pre-market

After hours

5.22

-0.03

0.57%

1 day

2.54%

5 days

-2.6%

1 month

-11.32%

3 months

-17.71%

6 months

-63.89%

Year to date

-67.08%

1 year

-47.18%

5 years

-11.47%

10 years

-78.31%

About: WAVE Life Sciences Inc is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

Employees: 317

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 30%

Neutral 60%

Negative 10%

24/7 Wall Street

Wave Life Sciences: A $1 Billion RNA-Medicine Bargain Ripe for Pharma Takeover

Wave Life Sciences (NASDAQ:WVE) trades at $5.24, a step above its 52-week low of $5.01 and far beneath the 52-week high of $21.73.

Wave Life Sciences: A $1 Billion RNA-Medicine Bargain Ripe for Pharma Takeover

Wave Life Sciences Ltd. (WVE) Presents at Bank of America SMID Cap Virtual Conference Transcript

Wave Life Sciences Ltd. (WVE) Presents at Bank of America SMID Cap Virtual Conference Transcript

Wave Life Sciences Ltd. (WVE) Presents at Bank of America SMID Cap Virtual Conference Transcript

Wave Life Sciences Announces Completion of Redomiciliation to Delaware

CAMBRIDGE, Mass., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (NASDAQ: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health (“Wave” or “Wave Life Sciences”), today announced the completion of the redomiciliation process to change the parent company of the Wave group of companies from a Singapore company to a Delaware corporation by way of a statutory procedure known as a scheme of arrangement under Section 210 of the Companies Act 1967 of Singapore (the “Redomiciliation”).

Wave Life Sciences Announces Completion of Redomiciliation to Delaware

Wave Life Sciences Announces Expected Completion Date for Redomiciliation to Delaware

CAMBRIDGE, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- As previously announced, Wave Life Sciences Ltd.

Wave Life Sciences Announces Expected Completion Date for Redomiciliation to Delaware

Wave Life Sciences to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that members of Wave's management team are scheduled to participate in two upcoming investor conferences in August.

Wave Life Sciences to Present at Upcoming Investor Conferences

WAVE Life Sciences Q2 Earnings Call Highlights

WAVE Life Sciences NASDAQ: WVE reported a wider second-quarter loss as it increased investment in its obesity and RNA-editing programs, while outlining several clinical and regulatory milestones expected in the second half of 2026.

WAVE Life Sciences Q2 Earnings Call Highlights

Wave Life Sciences Ltd. (WVE) Q2 2026 Earnings Call Transcript

Wave Life Sciences Ltd. (WVE) Q2 2026 Earnings Call Transcript

Wave Life Sciences Ltd. (WVE) Q2 2026 Earnings Call Transcript

Zacks Investment Research

Wave Life Sciences (WVE) Reports Q2 Loss, Misses Revenue Estimates

Wave Life Sciences (WVE) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.31 per share a year ago.

Wave Life Sciences (WVE) Reports Q2 Loss, Misses Revenue Estimates

Wave Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Dosing underway in Phase 2a multidose portion of the INLIGHT TM trial of WVE-007 (INHBE GalNAc-siRNA) in individuals with obesity (BMI: 35-50 kg/m 2 ) and comorbidities; trial will also inform WVE-007's potential in MASH, type 2 diabetes, and other cardiometabolic diseases

Wave Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Wave Life Sciences Second Quarter 2026 Financial Results Scheduled for July 30, 2026

CAMBRIDGE, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Thursday, July 30, 2026, to review the company's second quarter 2026 financial results and provide business updates.

Wave Life Sciences Second Quarter 2026 Financial Results Scheduled for July 30, 2026

See News Rankings

Price charts implemented using Lightweight Charts™